First, he can't grant himself anything. The BOD has to approve. So, your argument is FUNDAMENTALLY FLAWED unless you believe the BOD does not care about shareholders...like Adage, Fidelity, Broadwin, Blackrock, et. LOL!
The BOD understands what Dan has done already and its value to them DESPITE current pps...literally hundreds of millions in value. Further, the BOD knows what Dan is doing that we do not yet know about. The share award is a "tell" that big things are coming soon. Whatever Dan, Sara, etc. get in comp will be worth it if our market cap goes to $1B, $2B, yes, $6B. If they don't perform, their stock and options will be worth diddly-squat...same as us, fbg. Their fate is our fate and vice versa.
Based on past performance, I have no doubt DOC will create significant further value for shareholders. Current pps is not relevant, period. I trust our heavy-hitter co-investors to support the BOD's comp plan, which they (mostly) did in the recent shareholder vote.
People's focus on ADXS management comp is weird to me, honestly. If people want share price to efficiently reflect value potential, then they should be invested in major market average ETFs, not biotech.
So, three cheers for Dan, buying shares regularly and not selling anything (except to cover tax obligations), and his management team. Awesome job they are doing in generating tangible business results (e.g., efficient funding, trial strategy, EU application). Couldn't be happier with them. Worth every penny. In time, we all will do well.
